Pharmacogenomics of third-generation aromatase inhibitors

Bibliography

• Breast cancer statistics. American Cancer Society. Available from: www.cancer.org [Last accessed 1 March 2012]
   Google Scholar
• Breast cancer statistics. Canadian Cancer Society. Available from: www.cancer.ca [Last accessed 1 March 2012]
   Google Scholar
• Bulun SE, Takayama K, Suzuki T, Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med 2004;22:5-9
   PubMed Web of Science ®Google Scholar
• Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol 2001;45:S116-24
   PubMed Web of Science ®Google Scholar
• Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-30
   PubMed Web of Science ®Google Scholar
• Brodie A, Inkster S. Aromatase in the human testis. J Steroid Biochem Mol Biol 1993;44:549-55
   PubMed Web of Science ®Google Scholar
• Larionov AA, Vasyliev DA, Mason JI, Aromatase in skeletal muscle. J Steroid Biochem Mol Biol 2003;84:485-92
   PubMed Web of Science ®Google Scholar
• Sasano H, Uzuki M, Sawai T, Aromatase in human bone tissue. J Bone Miner Res 1997;12:1416-23
   PubMed Web of Science ®Google Scholar
• Sawaya ME, Penneys NS. Immunohistochemical distribution of aromatase and 3B-hydroxysteroid dehydrogenase in human hair follicle and sebaceous gland. J Cutan Pathol 1992;19:309-14
   PubMed Web of Science ®Google Scholar
• Bulun SE, Sharda G, Rink J, Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metab 1996;81:1273-7
   PubMed Web of Science ®Google Scholar
• Thompson EA Jr, Siiteri PK. Subcellular distribution of aromatase in human placenta and ovary. Horm Res 1979;11:179-85
   PubMedGoogle Scholar
• Biegon A, Kim SW, Alexoff DL, Unique distribution of aromatase in the human brain: in vivo studies with PET and [N-methyl-11C] vorozole. Synapse 2010;64:801-7
   PubMed Web of Science ®Google Scholar
• Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004;9:126-36
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22
   PubMed Web of Science ®Google Scholar
• Ingle JN. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology (Williston Park) 2001;15:28-34
   PubMed Web of Science ®Google Scholar
• Colleoni M, Gelber S, Goldhirsch A, Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006;24:1332e41
   Web of Science ®Google Scholar
• Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008;19:16-27
   PubMed Web of Science ®Google Scholar
• Lazarus P, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev 2010;42:182-94
   PubMed Web of Science ®Google Scholar
• Evans TR, Di Salle E, Ornati G, Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992;52:5933-9
   PubMed Web of Science ®Google Scholar
• Yates RA, Dowsett M, Fisher GV, Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996;73:543-8
   PubMed Web of Science ®Google Scholar
• Lipton A, Demers LM, Harvey HA, Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995;75:2132-8
   PubMed Web of Science ®Google Scholar
• Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007;18(Suppl 8):26-35
   Google Scholar
• Mouridsen HT. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin 2006;22:1609-21
   PubMed Web of Science ®Google Scholar
• Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011;13:205
   PubMed Web of Science ®Google Scholar
• Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 2005;93:23-7
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clin Interv Aging 2008;3:647-57
   PubMed Web of Science ®Google Scholar
• Santoro S, Santini M, Pepe C, Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol 2011;25:596-8
   PubMed Web of Science ®Google Scholar
• Muslimani AA, Spiro TP, Chaudhry AA, Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 2009;9:34-8
   PubMed Web of Science ®Google Scholar
• Ingle JN. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008;112:695-9
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Pharmacogenomics of endocrine therapy in breast cancer. Adv Exp Med Biol 2008;630:220-31
   PubMed Web of Science ®Google Scholar
• Ma CX, Adjei AA, Salavaggione OE, Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071-82
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011;62:281-93
   PubMed Web of Science ®Google Scholar
• Kamdem LK, Liu Y, Stearns V, In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010;70:854-69
   PubMed Web of Science ®Google Scholar
• Ingle JN, Buzdar AU, Schaid DJ, Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010;70:3278-86
   PubMed Web of Science ®Google Scholar
• Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 2004;64:1190-6
   PubMed Web of Science ®Google Scholar
• Ehmer U, Vogel A, Schutte JK, Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 2004;39:970-7
   PubMed Web of Science ®Google Scholar
• Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011;39:98-105
   PubMed Web of Science ®Google Scholar
• Sachse C, Bhambra U, Smith G, Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003;55:68-76
   PubMed Web of Science ®Google Scholar
• Napoli N, Villareal DT, Mumm S, Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res 2005;20:232-9
   PubMed Web of Science ®Google Scholar
• Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms – potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 2004;160:825-41
   PubMed Web of Science ®Google Scholar
• Cho BH, Park BL, Kim LH, Highly polymorphic human CYP4A11 gene. J Hum Genet 2005;50:259-63
   PubMed Web of Science ®Google Scholar
• Mikhailova ON, Gulyaeva LF, Prudnikov AV, Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J 2006;6:189-93
   PubMed Web of Science ®Google Scholar
• Sun D, Chen G, Dellinger RW, Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics 2010;20:575-85
   PubMed Web of Science ®Google Scholar
• Wilson W III, Pardo-Manuel de Villena F, Lyn-Cook BD, Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004;84:707-14
   PubMed Web of Science ®Google Scholar
• Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003;197:1279-8
   PubMed Web of Science ®Google Scholar
• Jeong S, Woo MM, Flockhart DA, Desta Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol 2009;64:867-75
   PubMed Web of Science ®Google Scholar
• Murai K, Yamazaki H, Nakagawa K, Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 2009;39:795-802
   PubMed Web of Science ®Google Scholar
• Desta Z, Kreutz Y, Nguyen AT, Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 2011;90:693-700
   PubMed Web of Science ®Google Scholar
• Colomer R, Monzo M, Tusquets I, A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14:811-16
   PubMed Web of Science ®Google Scholar
• Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 2010;10:36
   PubMed Web of Science ®Google Scholar
• Fasching PA, Loehberg CR, Strissel PL, Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 2008;112:89-98
   PubMed Web of Science ®Google Scholar
• Wang L, Ellsworth KA, Moon I, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010;70:319-28
   PubMed Web of Science ®Google Scholar
• Mao JJ, Su HI, Feng R, Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 2011;13:R8
   Web of Science ®Google Scholar
• Haiman CA, Hankinson SE, Spiegelman D, A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-10
   PubMed Web of Science ®Google Scholar
• Zarrabeitia MT, Hernandez JL, Valero C, A common polymorphism in the 5'-untranslated region of the aromatase gene influences bone mass and fracture risk. Eur J Endocrinol 2004;150:699-704
   PubMed Web of Science ®Google Scholar
• Ingle JN, Schaid DJ, Goss PE, Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010;28:4674-82
   PubMed Web of Science ®Google Scholar